Research: TB

Tuberculosis and HIV Immune Reconstitution Syndrome Trial (THIRST)

A pilot study of fixed dose combination zidovudine/lamivudine/abacavir in HIVinfected persons with tuberculosis in Moshi, Tanzania

This study, which we believe is the first controlled trial of antiretroviral therapy for HIV infected individuals in Tanzania, randomizes patients co-infected with HIV and tuberculosis to receive antiretroviral therapy either two weeks or eight weeks after initiating antituberculosis therapy.   40 subjects have enrolled in this study to date. With total accrual planned for 70 subjects, this study is projected to be fully enrolled by July 2005. A 24 week analysis should be completed in the Fall 2006.